Literature DB >> 25419525

IDENTIFICATION OF VDR ANTAGONISTS AMONG NUCLEAR RECEPTOR LIGANDS USING VIRTUAL SCREENING.

Kelly Teske1, Premchendar Nandhikonda1, Jonathan W Bogart1, Belaynesh Feleke1, Preetpal Sidhu1, Nina Yuan1, Joshua Preston1, Robin Goy1, Lanlan Han1, Nicholas R Silvaggi1, Rakesh K Singh2, Daniel D Bikle3, James M Cook1, Leggy A Arnold1.   

Abstract

Herein, we described the development of two virtual screens to identify new vitamin D receptor (VDR) antagonists among nuclear receptor (NR) ligands. Therefore, a database of 14330 nuclear receptor ligands and their NR affinities was assembled using the online available "Binding Database". Two different virtual screens were carried out in conjunction with a reported VDR crystal structure applying a stringent and less stringent pharmacophore model to filter docked NR ligand conformations. The pharmacophore models were based on the spatial orientation of the hydroxyl functionalities of VDR's natural ligands 1,25(OH2)D3 and 25(OH2)D3. The first virtual screen identified 32 NR ligands with a calculate free energy of VDR binding of more than -6.0 kJ/mol. All but nordihydroguaiaretic acid (NDGA) are VDR ligands, which inhibited the interaction between VDR and coactivator peptide SRC2-3 with an IC50 value of 15.8 µM. The second screen identified 162 NR ligands with a calculate free energy of VDR binding of more than -6.0 kJ/mol. More than half of these ligands were developed to bind VDR followed by ERα/β ligands (26%), TRα/β ligands (7%) and LxRα/β ligands (7%). The binding between VDR and ERα ligand H6036 as well as TRα/β ligand triiodothyronine and a homoserine analog thereof was confirmed by fluorescence polarization.

Entities:  

Keywords:  Virtual screening; estrogen receptor; nuclear receptor; thyroid receptor; vitamin D receptor

Year:  2014        PMID: 25419525      PMCID: PMC4240308          DOI: 10.11131/2014/101076

Source DB:  PubMed          Journal:  Nucl Receptor Res        ISSN: 2314-5706


  26 in total

1.  Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.

Authors:  Nathan A Lack; Peter Axerio-Cilies; Peyman Tavassoli; Frank Q Han; Ka Hong Chan; Clementine Feau; Eric LeBlanc; Emma Tomlinson Guns; R Kiplin Guy; Paul S Rennie; Artem Cherkasov
Journal:  J Med Chem       Date:  2011-11-18       Impact factor: 7.446

Review 2.  Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update.

Authors:  Jian-Ming Lü; Jacobo Nurko; Sarah M Weakley; Jun Jiang; Panagiotis Kougias; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Med Sci Monit       Date:  2010-05

Review 3.  How many drug targets are there?

Authors:  John P Overington; Bissan Al-Lazikani; Andrew L Hopkins
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

Review 4.  Vitamin D receptor ligands: the impact of crystal structures.

Authors:  Carsten Carlberg; Ferdinand Molnár; Antonio Mouriño
Journal:  Expert Opin Ther Pat       Date:  2012-03-27       Impact factor: 6.674

5.  Evidence for a new kidney-produced hormone, 1,25-dihydroxycholecalciferol, the proposed biologically active form of vitamin D.

Authors:  A W Norman
Journal:  Am J Clin Nutr       Date:  1971-11       Impact factor: 7.045

6.  Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.

Authors:  Pierre-Yves Michellys; Marcus F Boehm; Jyun-Hung Chen; Timothy A Grese; Donald S Karanewsky; Mark D Leibowitz; Sha Liu; Dale A Mais; Christopher M Mapes; Anne Reifel-Miller; Katheen M Ogilvie; Deepa Rungta; Anthony W Thompson; John S Tyhonas; Nathan Yumibe; Robert J Ardecky
Journal:  Bioorg Med Chem Lett       Date:  2003-11-17       Impact factor: 2.823

7.  Quantification of the vitamin D receptor-coregulator interaction.

Authors:  Arnaud Teichert; Leggy A Arnold; Steve Otieno; Yuko Oda; Indre Augustinaite; Tim R Geistlinger; Richard W Kriwacki; R Kiplin Guy; Daniel D Bikle
Journal:  Biochemistry       Date:  2009-02-24       Impact factor: 3.162

8.  Removal of the 20-methyl group from 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D(3) (2MD) selectively eliminates bone calcium mobilization activity.

Authors:  Rafal Barycki; Rafal R Sicinski; Lori A Plum; Pawel Grzywacz; Margaret Clagett-Dame; Hector F Deluca
Journal:  Bioorg Med Chem       Date:  2009-09-29       Impact factor: 3.641

9.  Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators.

Authors:  Premchendar Nandhikonda; Wen Z Lynt; Megan M McCallum; Tahniyath Ara; Athena M Baranowski; Nina Y Yuan; Dana Pearson; Daniel D Bikle; R Kiplin Guy; Leggy A Arnold
Journal:  J Med Chem       Date:  2012-05-16       Impact factor: 7.446

10.  Peroxisome proliferation-activated receptor δ agonist GW0742 interacts weakly with multiple nuclear receptors, including the vitamin D receptor.

Authors:  Premchendar Nandhikonda; Adam Yasgar; Athena M Baranowski; Preetpal S Sidhu; Megan M McCallum; Alan J Pawlak; Kelly Teske; Belaynesh Feleke; Nina Y Yuan; Chinedum Kevin; Daniel D Bikle; Steven D Ayers; Paul Webb; Ganesha Rai; Anton Simeonov; Ajit Jadhav; David Maloney; Leggy A Arnold
Journal:  Biochemistry       Date:  2013-06-10       Impact factor: 3.321

View more
  5 in total

1.  Anticancer activity of VDR-coregulator inhibitor PS121912.

Authors:  Preetpal S Sidhu; Kelly Teske; Belaynesh Feleke; Nina Y Yuan; Margaret L Guthrie; Grant B Fernstrum; Nishita D Vyas; Lanlan Han; Joshua Preston; Jonathan W Bogart; Nicholas R Silvaggi; James M Cook; Rakesh K Singh; Daniel D Bikle; Leggy A Arnold
Journal:  Cancer Chemother Pharmacol       Date:  2014-08-09       Impact factor: 3.333

Review 2.  Inhibitors for the Vitamin D Receptor-Coregulator Interaction.

Authors:  Kelly A Teske; Olivia Yu; Leggy A Arnold
Journal:  Vitam Horm       Date:  2015-11-30       Impact factor: 3.421

3.  Novel VDR antagonists based on the GW0742 scaffold.

Authors:  Kelly A Teske; Jonathan W Bogart; Leggy A Arnold
Journal:  Bioorg Med Chem Lett       Date:  2017-12-19       Impact factor: 2.940

4.  Discriminating agonist and antagonist ligands of the nuclear receptors using 3D-pharmacophores.

Authors:  Nathalie Lagarde; Solenne Delahaye; Jean-François Zagury; Matthieu Montes
Journal:  J Cheminform       Date:  2016-09-06       Impact factor: 5.514

Review 5.  Relationship between Structure and Conformational Change of the Vitamin D Receptor Ligand Binding Domain in 1α,25-Dihydroxyvitamin D3 Signaling.

Authors:  Lin-Yan Wan; Yan-Qiong Zhang; Meng-Di Chen; You-Qin Du; Chang-Bai Liu; Jiang-Feng Wu
Journal:  Molecules       Date:  2015-11-18       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.